Company intelligence / Profile preview
HERVolution Therapeutics
Copenhagen, Denmarkhervolutiontx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
HERVolution Therapeutics has developed a proprietary platform that enables the immune system to recognize and attack previously undruggable tumor-specific antigens derived from human endogenous retroviruses. Their lead candidate IPT‑001 has shown robust preclinical data and aims to address cancer as well as aging-related conditions. Clinical entry for their first program is expected in 2025. The company recently raised $11.7M Series A funding to advance its pipeline.
- Therapeutic areas
- OtherOncologyNeurologyMetabolic Disorders
- Modalities
- Immunotherapy (specifically dual adenoviral vector immune therapy)Engineered antigens targeting Human Endogenous Retroviruses (HERVs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on HERVolution Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HERVolution Therapeutics.